NurExone Biologic to Participate in 2022 Bio-Europe Conference

Calgary, Alberta--(Newsfile Corp. - October 20, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that the Company will be participating in the upcoming 2022 Bio-Europe Conference ("Bio-Europe") in Leipzig, Germany, which commences on October 24th and ends on October 26th.

Bio-Europe is regarded as one of Europe's largest gathering of professionals in the biopharma industry.¹ Over 4000 attendees and more than 2200 companies from around the world are expected to attend this prestigious event.²

NurExone's CEO, Dr. Lior Shaltiel, and Dr. Lyora Aharonov, Director of R&D, will attend the conference to promote the Company's revolutionary exosome-based drug platform, ExoTherapy. In addition, the Company intends to establish new business relationships with companies within the biopharma space to secure more strategic collaborations and partnerships that can accelerate NurExone's growth.

"We are delighted to participate in the upcoming Bio-Europe conference where we can raise more awareness about our exosome-based technology in front of a global audience," said Dr. Lior Shaltiel, CEO of NurExone. "This event provides us with the opportunity to meet and connect with top professionals within the biopharma industry where we exchange ideas as well as potentially secure new strategic partnerships that will enable us to advance the development of our unique drug platform. We look forward to attending the conference."

Attendees can schedule a meeting with NurExone's team to learn more about the Company and its drug platform during the event. The team will be available for in-person meetings throughout the conference. To request a meeting, please reach out to the info@nurexone.com.

For more information about Bio-Europe, please visit: https://informaconnect.com/bioeurope/.

About NurExone Biologic Inc.

NurExone Biologic Inc. is a TSXV listed pharmaceutical company developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries. ExoTherapy was so far conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. and the company is translating the treatment to humans. Nurexone holds an exclusive worldwide license from the Technion and Tel Aviv University for the development and commercialization of the technology.

For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

For more information, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: lior@nurexone.com

For investors:
Investor Relations
IR@nurexone.com
+1 905-347-5569

FORWARD-LOOKING STATEMENTS

This press release contains certain forward-looking statements, including statements about the Company's future plans and development activities to be carried out by the company, future potential manufacturing and marketing activities and the treatment of certain conditions. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the Company's early stage of development, lack of revenues to date, government regulation, market acceptance for its products, rapid technological change, dependence on key personnel, protection of the Company's intellectual property and dependence on the Company's strategic partners. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

1. https://informaconnect.com/bioeurope/
2. https://informaconnect.com/bioeurope/attendees/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/141165